RU-58642

From Wikipedia, the free encyclopedia
Jump to: navigation, search
RU-58642
RU58642.svg
Systematic (IUPAC) name
4-[3-(cyanomethyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
Clinical data
Legal status
?
Identifiers
CAS number 143782-63-2
ATC code ?
PubChem CID 9840708
Chemical data
Formula C15H11F3N4O2 
Mol. mass 336.268 g/mol

RU-58642 is a non-steroidal anti-androgen drug with very high affinity and selectivity, which made it among the most potent and effective antiandrogen drugs known at the time of its discovery.[1] It was investigated for topical application for the treatment of baldness, but development did not proceed past initial trial stages, and it is now only used for scientific research into the androgen receptor.[2][3]

References[edit]

  1. ^ Battmann, T.; Branche, C.; Bouchoux, F.; Cerede, E.; Philibert, D.; Goubet, F.; Teutsch, G.; Gaillard-Kelly, M. (1998). "Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders". The Journal of Steroid Biochemistry and Molecular Biology 64 (1–2): 103–111. doi:10.1016/S0960-0760(97)00151-9. PMID 9569015.  edit
  2. ^ Sims, N. A.; Clément-Lacroix, P.; Minet, D.; Fraslon-Vanhulle, C.; Gaillard-Kelly, M.; Resche-Rigon, M. L.; Baron, R. (2003). "A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor–deficient mice". Journal of Clinical Investigation 111 (9): 1319–1327. doi:10.1172/JCI17246. PMC 154447. PMID 12727923.  edit
  3. ^ Windahl, S. H.; Galien, R.; Chiusaroli, R.; Clément-Lacroix, P.; Morvan, F.; Lepescheux, L. N.; Nique, F. O.; Horne, W. C.; Resche-Rigon, M. L.; Baron, R. (2006). "Bone protection by estrens occurs through non–tissue-selective activation of the androgen receptor". Journal of Clinical Investigation 116 (9): 2500–2509. doi:10.1172/JCI28809. PMC 1555662. PMID 16955145.  edit